Ofacitix 5mg Tablet contains Tofacitinib, a Janus kinase (JAK) inhibitor indicated for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in adult patients. By selectively inhibiting JAK enzymes, Ofacitix modulates the signaling pathways involved in the inflammatory process, thereby reducing joint inflammation, pain, and structural damage. It is prescribed for patients who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). The recommended dosage is 5mg administered orally twice daily, with adjustments based on clinical response and tolerability. Ofacitix may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs. Common adverse effects include upper respiratory tract infections, headache, and gastrointestinal disturbances. Serious risks involve infections, malignancies, and thrombosis; therefore, patients should be monitored regularly for signs of infection, blood counts, and lipid profiles during treatment. Ofacitix is contraindicated in patients with active infections and should be used cautiously in those with a history of chronic infections or immunodeficiency. It is essential to evaluate the benefit-risk ratio before initiating therapy and to adhere to recommended monitoring guidelines to ensure patient safety and therapeutic efficacy.